Janet Cady:	has nothing to disclose
Erica D. Koval;	has nothing to disclose
Bruno A. Benitez;	has nothing to disclose
Jennifer Jockel-Balsarotti:	has nothing to disclose
Peggy Allred:	has nothing to disclose
Robert H. Baloh:	has nothing to disclose
John Ravits: receives research support from the ALS Association, Microsoft Research, P2ALS. Serves as an unpaid consultant to the Muscular Dystrophy Association Consults for Isis Pharmaceuticals, Inc.
Ericka Simpson:	has nothing to disclose
Stanley H. Appel:	receives grant support from the Hamill foundation outside the submitted work
Alan Pestronk: Receives revenue related to antibody patent licenses & speaker honoraria from Athena; Owns stock in Johnson & Johnson; Directs the Washington University Neuromuscular Clinical Laboratory which performs antibody testing; Receives research support from the NIH, Muscular Dystrophy Association, Neuromuscular Research Fund; Insmed, Knopp, Cytokinetics, Biogen Idec, ISIS, Genzyme, GSK, Sanofi & Ultragenyx.
Alison M. Goate: Provides consultation or expert testimony to Finnegan Receives grants from Genetech, Pfizer, and Astrazeneca for Alzheimer’s genetic research Has received honoraria from Genentech and Amgen for speaking on Alzheimer’s genetics Receives royalties from Taconic for tau mutation patents
Timothy M. Miller: Non-financial support from Regulus Therapeutics, outside the submitted work Grants and non-financial support from Isis Pharmaceuticals, outside the submitted work Has a patent inhibiting miR-155 in ALS pending.
Carlos Cruchaga:	has nothing to disclose
Matthew B. Harms: Has received honoraria from Genzyme for speaking on neuromuscular genetics Has provided expert testimony in medicolegal proceedings Has received grant support from Ultragenyx, outside the submitted work Receives grant funding from the Barnes Jewish Foundation and NIH